Regulatory
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive NMIBC
October 14, 2026
Biotech
Regulatory
Key Facts
Signal Type
Regulatory
Industry
Biotech
Companies
ImmunityBio, National Comprehensive Cancer Network
Date
October 14, 2026
On October 14, 2026, the FDA expanded the indication for ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) plus BCG to include adults with BCG-unresponsive, high-grade non-muscle invasive bladder cancer with papillary-only tumors. The action revises the April 2024 indication, which was limited to disease with carcinoma in situ with or without papillary tumors.
Rather than relying on a new trial, the FDA determined that efficacy shown in patients with CIS could be extrapolated to high-grade papillary disease. The decision arrived ahead of the January 6, 2027, PDUFA target date announced when the supplemental application was accepted in May 2026.
The expanded label affects adults with BCG-unresponsive, high-grade NMIBC whose tumors are papillary-only, removing the prior requirement for CIS. It also touches ImmunityBio's regulatory, medical affairs, and commercial teams responsible for communicating the new indication and supporting urology and oncology practices.
The FDA noted that high-grade papillary tumors and CIS frequently coexist, can be difficult to distinguish pathologically, and carry a high risk of recurrence and progression in the BCG-unresponsive setting, so the broader label may change diagnostic classification and treatment planning.
The label expansion broadens the eligible patient population for Anktiva plus BCG in the BCG-unresponsive NMIBC setting. In March 2026, the National Comprehensive Cancer Network had already added the combination as a category 2A option for BCG-unresponsive papillary-only disease.
The FDA said it is working to finalize its draft guidance on drug development for BCG-unresponsive NMIBC to address this extrapolation approach. Watch for updated guidance language and any further NCCN or clinical practice changes.
Cohort B results -- the basis of the supplemental application -- came from a single-arm trial without a comparator, so future comparative or real-world evidence could affect adoption. The prescribing information continues to warn that delaying cystectomy can lead to metastatic bladder cancer, which may factor into treatment decisions.
Source:
Oncology Nursing NewsGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
